

Resource Summary Report

Generated by [kravitz2](#) on Aug 1, 2026

Agilent: RapidFire 365 High-Throughput Mass Spectrometry System

RRID:SCR_019530

Type: Tool

Proper Citation

Agilent: RapidFire 365 High-Throughput Mass Spectrometry System (RRID:SCR_019530)

Resource Information

URL: <https://www.agilent.com/en/products/liquid-chromatography-mass-spectrometry-lc-ms/lc-ms-instruments/high-throughput-lc-ms/rapidfire-365>

Proper Citation: Agilent: RapidFire 365 High-Throughput Mass Spectrometry System (RRID:SCR_019530)

Description: Mass Spectrometry System replaces HPLC with automated solid phase extraction SPE to increase throughput of LC MS analyses.

Resource Type: instrument resource

Keywords: Agilent, High-Throughput LC/MS, Instrument Equipment, USEDit,

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_019530.pdf

Resource Name: Agilent: RapidFire 365 High-Throughput Mass Spectrometry System

Resource ID: SCR_019530

Alternate IDs: Model_Number_RapidFire 365

Record Creation Time: 20220129T080345+0000

Record Last Update: 20260725T190914+0000

Ratings and Alerts

No rating or validation information has been found for Agilent: RapidFire 365 High-Throughput Mass Spectrometry System.

No alerts have been found for Agilent: RapidFire 365 High-Throughput Mass Spectrometry System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Šimelis K, et al. (2024) Unravelling 2-oxoglutarate turnover and substrate oxidation dynamics in 5-methylcytosine-oxidising TET enzymes. *Communications chemistry*, 7(1), 305.

Wei Z, et al. (2024) Use of in vitro methods combined with in silico analysis to identify potential skin sensitizers in the Tox21 10K compound library. *Frontiers in toxicology*, 6, 1321857.

Belle R, et al. (2024) Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate. *Journal of medicinal chemistry*, 67(6), 4525.

Barkan DT, et al. (2024) Identification of Potent, Broad-Spectrum Coronavirus Main Protease Inhibitors for Pandemic Preparedness. *Journal of medicinal chemistry*, 67(19), 17454.

Balçık E, et al. (2024) Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist. *Journal of medicinal chemistry*, 67(9), 7245.

Go MK, et al. (2023) Cannabinoid Biosynthesis Using Noncanonical Cannabinoid Synthases. *International journal of molecular sciences*, 24(2).

Medvedíková M, et al. (2023) Highly Cytotoxic Copper(II) Mixed-Ligand Quinolinonato Complexes: Pharmacokinetic Properties and Interactions with Drug Metabolizing Cytochromes P450. *Pharmaceutics*, 15(4).

Belle R, et al. (2022) Reading and erasing of the phosphonium analogue of trimethyllysine by epigenetic proteins. *Communications chemistry*, 5(1).

Pearson LA, et al. (2021) Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry. *SLAS discovery : advancing life sciences R & D*, 26(6), 749.

Nowak RP, et al. (2021) First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. *Journal of medicinal chemistry*, 64(23), 17031.

Wei Z, et al. (2021) A direct peptide reactivity assay using a high-throughput mass spectrometry screening platform for detection of skin sensitizers. *Toxicology letters*, 338, 67.

Clausse V, et al. (2019) Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. *The Journal of biological chemistry*, 294(46), 17654.

Matico R, et al. (2019) Modular Protein Ligation: A New Paradigm as a Reagent Platform for Pre-Clinical Drug Discovery. *Scientific reports*, 9(1), 13078.

Dai H, et al. (2016) Synthesis and Assay of SIRT1-Activating Compounds. *Methods in enzymology*, 574, 213.